Brief: Vir Biotechnology Says Tobevibart And Elebsiran Achieve 100% Virologic Suppression At Week 24
19/11/2024 02:16
Nov 18 (Reuters) - Vir Biotechnology Inc VIR.O :
* VIR BIOTECHNOLOGY PRESENTS POSITIVE CHRONIC HEPATITIS
DELTA
CLINICAL TRIAL DATA AND ANNOUNCES INITIATION OF PHASE 3
REGISTRATIONAL PROGRAM
* VIR BIOTECHNOLOGY INC - TOBEVIBART AND ELEBSIRAN ACHIEVE
100%
VIROLOGIC SUPPRESSION AT WEEK 24
* VIR BIOTECHNOLOGY INC - PHASE 3 ECLIPSE PROGRAM TO
EVALUATE
TOBEVIBART AND ELEBSIRAN
* VIR BIOTECHNOLOGY INC - PHASE 3 ECLIPSE PROGRAM TO BEGIN
IN
FIRST HALF OF 2025
* VIR BIOTECHNOLOGY INC - EMA ISSUES POSITIVE OPINION ON
ORPHAN
DRUG DESIGNATION FOR TOBEVIBART AND ELEBSIRAN
Source text: ID:nBw8P6gjwa
Further company coverage: VIR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vir Biotechnology
See all newsVir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
Brief: Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation For The Treatment Of Prostate Cancer
Brief: Vir Biotechnology Appoints David Liu As Chief Medical Officer
Vir Biotechnology rises after naming Theravance's Sawaf as CFO